Classified: Next-Gen Sequencing Analyzers, Mobile Glucose Monitoring, Restless-Leg Devices
Executive Summary
FDA issued orders officially finalizing regulatory classifications and special controls for next-generation sequencing analyzers; "secondary display" devices for continuous glucose monitor data; and vibratory counter-stimulation devices for restless leg syndrome. And the agency is working towards formalizing 510(k) exemptions for future devices of these types as well.
You may also be interested in...
US FDA Lists Hundreds Of Devices For 510(k) Exemption
A list of devices being considered for 510(k) exemption includes allergens used in immune system testing, drug tests for employers and denture supplies. The agency is collecting comments through May 15.
US FDA's Next-Gen Sequencing Guidances: One Stop On A Pathway
Two recent next-generation sequencing draft guidances have been positively received so far by industry and clinical research groups. But for FDA's ideas to play out, more databases will need to be populated and more standards developed, agency officials say. There are also more guidances to come on different types of NGS tests. Read our coverage below, and also listen to our podcast interview with FDA's Elizabeth Mansfield.
FDA Approves DexCom Share Update, Downclassifies CGM Accessory
The agency approved DexCom’s new Share CGM receiver that works without a cradle and allows diabetes patients to share their medical data from anywhere. It also reclassified such devices to no longer require a premarket submission.